by Doug Bonness | Jan 28, 2016 | Pharmacogenomics
Since 2007, when the FDA acknowledged that a blood-thinning drug’s effectiveness (or lack of) could be determined by how a person’s unique genetic structure responded to dosage, the medical field has been questioning its trial-by-error methodology....
by Doug Bonness | Jan 27, 2016 | MD Heartpro
Research Current research shows that combining multiple markers, as these tests do, will help assess patients’ risks for cardiovascular problems. Recently, most doctors felt that heart attacks were simply a result of fatty deposits that built up, slowly, on...
by Doug Bonness | Jan 25, 2016 | Uncategorized
If you think that a routine lipid screening will be enough to accurately predict your heart attack risk level, think again. While it’s true that getting your cholesterol levels checked does a play an important part in your risk assessment, it does not give you...
